Veru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity Drugs.
- Author
- Water Tower Research
- Published
- Wed 26 Feb 2025
- Episode Link
- None
CEO Mitch Steiner joins us on this week’s collaboration with WTR Biotech Spotlight to talk about the next generation of drugs focusing on lean mass (muscle) preservation for obesity patients on the popular GLP-1 therapies. He reviews the recent enobosarm Phase 2b data and highlights the importance of functional clinical benefit in addition to maintaining lean mass. Listen to learn more about Veru and its obesity drug enobosarm.
